Vertex Pharmaceuticals Incorporated today announced business and program updates ahead of upcoming investor meetings in January, including the company's scheduled webcast from the 44th annual J.P.
Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million to support Teva’s anti-IL-15 candidate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback